3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Colorectal Neoplasms
445
Carcinoma, Non-Small-Cell Lung
224
Breast Neoplasms
189
Ovarian Neoplasms
167
Glioblastoma
156
Neoplasms
126
Carcinoma, Hepatocellular
124
Rectal Neoplasms
112
Colonic Neoplasms
107
Neoplasm Metastasis
104
Brain Neoplasms
96
Lung Neoplasms
91
Fallopian Tube Neoplasms
85
Carcinoma, Renal Cell
71
Glioma
69
Pancreatic Neoplasms
54
Gliosarcoma
43
Melanoma
42
Liver Neoplasms
42
Uterine Cervical Neoplasms
40
Stomach Neoplasms
37
Adenocarcinoma of Lung
36
Recurrence
33
Astrocytoma
30
Endometrial Neoplasms
27
Carcinoma, Ovarian Epithelial
27
Triple Negative Breast Neoplasms
26
Prostatic Neoplasms
22
Kidney Neoplasms
22
Esophageal Neoplasms
21
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
Bevacizumab
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts